Karolinska Development’s Board director Magnus Persson resigns from his position

STOCKHOLM, SWEDEN – 25 August, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that Magnus Persson has decided to resign from his position as member of the company’s Board of directors.

Magnus Persson has been a Board director of Karolinska Development since 2017. He is now leaving his post at his own request and with immediate effect, to focus on his role as founding partner in Eir Ventures, a recently started fund for investments in the life science sector.

For further information, please contact:

Björn Cochlovius, Board director, Karolinska Development AB

Tel: +49 151 17555444, e-mail:

TO THE EDITORS

About Karolinska Development AB



Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 18:30 CET on 25 August, 2020

Attachment